Biblio
“Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged AβPP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1157-73, 2016.
, “Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 2, pp. 445-56, 2016.
, “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
, “A Brief Computerized Paired Associate Test for the Detection of Mild Cognitive Impairment in Community-Dwelling Older Adults.”, J Alzheimers Dis, vol. 54, no. 2, pp. 793-9, 2016.
, “Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.”, J Alzheimers Dis, vol. 54, no. 3, pp. 913-922, 2016.
, “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
, “Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.
, “Cerebral Amyloid Angiopathy (CAA)-Related Inflammation: Comparison of Inflammatory CAA and Amyloid-β-Related Angiitis.”, J Alzheimers Dis, vol. 51, no. 2, pp. 525-32, 2016.
, “Cerebral Arterial Occlusion Did Not Promote the Prevalence of Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 54, no. 1, pp. 269-74, 2016.
, “Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults.”, J Alzheimers Dis, vol. 52, no. 2, pp. 661-72, 2016.
, “Cerebral Microbleeds and Cerebrovascular Reactivity in the General Population: The EDAN Study.”, J Alzheimers Dis, vol. 53, no. 2, pp. 497-503, 2016.
, “Cerebral Small Vessel Disease and Motoric Cognitive Risk Syndrome: Results from the Kerala-Einstein Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 699-707, 2016.
, “Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 351-7, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.”, J Alzheimers Dis, vol. 54, no. 1, pp. 287-95, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1291-1295, 2016.
, “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
, “Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 3, pp. 1055-64, 2016.
, “Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.”, J Alzheimers Dis, vol. 54, no. 2, pp. 597-613, 2016.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1523-38, 2016.
, “CerefolinNAC Therapy of Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer's Disease and Cerebrovascular Disease.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1073-1084, 2016.
, “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
, “Changes in Frailty Predict Changes in Cognition in Older Men: The Honolulu-Asia Aging Study.”, J Alzheimers Dis, vol. 53, no. 3, pp. 1003-13, 2016.
,